文献速递脑血管病认知障碍与痴呆

VasCog-2-WSO血管性认知障碍标准在无痴呆无卒中社区队列中的验证

Validation of the VasCog-2-WSO VCID Criteria in a Dementia-Free and Stroke-Free Community Cohort: Cardiovascular Risk and Mortality.
PubMed 文献 · Neurology · 2026-07-30

本研究在1236名无卒中无痴呆社区成人中验证VasCog-2-WSO VCID诊断标准,采用神经影像优先方法分类。随访9.4年发现,神经影像阳性组认知表现更差、心血管风险更高,死亡率随VCID谱系递增,临床前VCID即与死亡风险升高相关。

要点

  • VasCog-2-WSO标准可在社区识别MRI定义的血管性认知脆弱谱系。
  • 临床前VCID阶段即与全因死亡风险升高相关,支持早期识别。
  • VCID谱系与10年心血管风险和认知表现恶化呈梯度关联。

核心结论

  • VasCog-2-WSO标准识别出与心血管风险增加和死亡率升高相关的MRI定义血管性认知脆弱谱系。
  • 在明显认知障碍前的神经影像定义临床前阶段即可检测到超额死亡风险。

研究设计与样本

  • 基于I-Lan纵向衰老研究的社区队列研究,纳入1236名50岁及以上无卒中无痴呆成人(62.7±8.8岁,52.9%女性)。
  • 采用标准化脑MRI和综合神经心理学评估,按VasCog-2-WSO标准以神经影像优先方法分类。
  • 主要结局为平均随访9.4年的全因死亡率,使用多变量Cox比例风险和Poisson回归分析。

主要发现

  • 19.6%参与者存在脑血管病神经影像证据,19.2%符合临床前VCID标准,0.4%符合vaMCI标准。
  • 与非VCID相比,神经影像阳性组认知表现更差且10年心血管风险更高。
  • 死亡率随VCID谱系递增:非VCID 7.4(95%CI 5.7-9.4)、临床前VCID 24.9(16.0-37.1)、vaMCI 27.4(18.2-39.6)、另一组137.9(37.6-353.2)每1000人年。
  • 调整后Cox模型中,临床前VCID死亡风险高1.5-1.7倍,vaMCI风险比7.2(95%CI 2.4-21.1),谱系梯度关联显著(趋势p<0.001)。

关键数值与推荐

  • VasCog-2-WSO标准分类为非VCID、临床前VCID(伴或不伴客观认知障碍)和血管性轻度认知障碍(vaMCI)。

临床怎么用

  • 在社区环境中可依据VasCog-2-WSO标准进行早期检测和风险分层。
  • 对神经影像显示脑血管病但无痴呆者应关注心血管风险管理和死亡风险。

局限性

  • 缺乏遗传数据和阿尔茨海默病生物标志物,无法评估混合病因,限制了对VasCog-2-WSO VCID诊断框架的全面评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Vascular cognitive impairment and dementia (VCID), a major contributor of dementia, remains underrecognized, owing to the absence of universally accepted diagnostic criteria. The VasCog Society and WSO recently released updated criteria (VasCog-2-WSO); however, their applicability is unknown yet. We aimed to evaluate these criteria in a dementia-free and stroke-free community cohort and determine their associations with vascular burden and long-term mortality. METHODS: We conducted a community-based cohort study using data from the I-Lan Longitudinal Aging Study. Adults aged 50 years or older without prior stroke or dementia underwent standardized brain MRI and comprehensive neuropsychological assessment. VCID was classified according to the VasCog-2-WSO criteria using a neuroimaging-first approach. Participants were categorized as non-VCID, preclinical VCID (with or without objective cognitive impairment), or vascular mild cognitive impairment (vaMCI). Baseline 10-year Framingham cardiovascular disease risk was assessed. The primary outcome was all-cause mortality over a mean follow-up of 9.4 years, analyzed using multivariable Cox proportional hazards and Poisson regression models. RESULTS: A total of 1,236 participants (62.7 ± 8.8 years; 52.9% female) were included. Neuroimaging evidence of cerebrovascular disease was present in 19.6% of participants; 19.2% met criteria for preclinical VCID and 0.4% for vaMCI. Compared with non-VCID participants, neuroimaging-positive groups had worse cognitive performance and higher 10-year cardiovascular risk. Mortality increased across the VCID spectrum (7.4 [95% CI 5.7-9.4], 24.9 [16.0-37.1], 27.4 [18.2-39.6], and 137.9 [37.6-353.2] per 1,000 person-years). In adjusted Cox models, preclinical VCID was associated with a 1.5-1.7-fold higher mortality risk, and vaMCI with a hazard ratio of 7.2 (95% CI 2.4-21.1), with a significant graded association across the spectrum (p for trend <0.001). DISCUSSION: The VasCog-2-WSO criteria identify a spectrum of MRI-defined vascular cognitive vulnerability associated with increased cardiovascular risk and mortality, with excess mortality risk detectable at a neuroimaging-defined preclinical stage before overt cognitive impairment. These findings support their utility for early detection and risk stratification in community settings. A key limitation is the inability to assess mixed etiologies due to the absence of genetic data and Alzheimer disease biomarkers, which limits the ability to thoroughly evaluate the VasCog-2-WSO VCID diagnostic framework.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lin YR, Lee WJ, Lee PL, et al. Validation of the VasCog-2-WSO VCID Criteria in a Dementia-Free and Stroke-Free Community Cohort: Cardiovascular Risk and Mortality. Neurology. 2026. PMID: 42531538. doi:10.1212/WNL.0000000000218311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。